Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-led-global-study-sees-improvement-in-overall-survival-in-patients-with-advanced-lung-cancer
https://www.med.cuhk.edu.hk/press-releases/cuhk-led-global-study-sees-improvement-in-overall-survival-in-patients-with-advanced-lung-cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

A global study led by the Faculty of Medicine of The Chinese University of Hong Kong (CUHK) has revealed that a second generation targeted therapy shows a more than 7-month improvement in the overall survival of advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation, compared with conventional first-line treatment. More than half of these patients survived 30 months or more. This Phase 3 clinical trial demonstrates that the new treatment is superior to current treatment and should be considered one of the standard treatment options for these lung cancer patients. The results of the research were just published in the Journal of Clinical Oncology and presented to oncologists worldwide at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO), the largest and most influential oncology organisation in the world.

 

NSCLC accounts for 80% of all lung cancers, while over half of the patients with adenocarcinoma harbour EGFR mutation

Lung cancer is the most common cancer in the world, accounting for 1.6 million deaths every year. In Hong Kong, lung cancer is also the leading cause of cancer deaths and the second most common cancer with over 4,000 new cases per year, in which many of the patients are young female non-smokers.

 

NSCLC accounts for about 80% of all lung cancers. Adenocarcinoma is the majority of NSCLC and over half of lung cancer patients with adenocarcinoma harbour EGFR mutation.

 

Professor Tony Shu Kam MOK,Li Shu Fan Medical Foundation Professor of Clinical Oncology and Chairman of the Department of Clinical Oncology of the Faculty of Medicine at CUHK, established the role of first-generation tyrosine kinase inhibitor (TKI) “Gefitinib” as the standard-of-care in patients with EGFR mutation in 2009. With the rapid development of medical science, new generations of lung cancer targeted therapy have been developed in the past decade.

 

New therapy shows more than 7-month improvement in overall survival

To compare the efficacy and safety of treatment with the second-generation TKI “Dacomitinib” to conventional treatment with “Gefitinib” in patients with advanced NSCLC and EGFR mutation, Professor Tony MOK leads an international randomised phase 3 study named “ARCHER 1050” which involved 71 medical centres and hospitals worldwide. 

 

Previously reported findings from ARCHER 1050 showed that the progression-free survival (PFS) with Dacomitinib is over 1 year, six months longer than conventional treatment.

 

Results of the recent research have further revealed that the second-generation TKI improves overall survival as first-line treatment in patients with advanced NSCLC harbouring activating EGFR mutations. A total of 452 patients with advanced NSCLC with EGFR mutation were enrolled in the study, of which nearly 80% of them are Asians. 

 

The patients were randomly divided into two groups and assigned to Dacomitinib or Gefitinib. Results show that overall survival in the Dacomitinib group was almost 3 years and there is a 7-month improvement, while the overall survival probabilities at 30 months is also better. Study results are summarized as below:

 

 Second-generation TKI
Dacomitinib
227 patients
Conventional TKI Gefitinib
225 patients
Overall survivalmedian34 months27 months
Overall survival probabilities
(at 30 months)
56%46%
No. of patient developed brain metastases111

 

In addition, patients in Dacomitinib group who needed chemotherapy as subsequent treatment was 10% lower than that in the Gefitinib group.  

 

Phase 3 Study demonstrates better efficacy and safety than conventional treatment

While presenting the above findings at the 54th ASCO annual meeting held in early June this year, Professor Tony MOK pointed out, “Overall survival is an important measure to assess efficacy of a new cancer treatment. The importance of the study is that it is the first phase 3 randomised clinical study that directly compares two TKIs as first-line treatments and shows an improvement in overall survival. Results show that the new treatment improves both the progression-free survival and overall survival of the patients. I look forward to having the novel targeted therapy as a potential first-line treatment option for NSCLC patients with EGFR mutations.”

 

Professor Mok added, “Having said that, we should also note the toxicity involved in Dacomitinib.  The most common adverse event reported was diarrhoea of which more than 80% of patients experienced. Some patients even had to discontinue due to treatment-related adverse events. After all, we have to watch out on toxicity management in this connection.”

 

Asia continues to make global impact on lung cancer research

Professor Mok established the role of first-line treatment in patients with EGFR mutation in 2009, later suggesting a new treatment paradigm for patients whose cancer genes further mutate and develop resistance after first-line EGFR targeted therapy in 2016. The latter study was selected as one of the ten most “Notable Articles of 2017” by a top medical journal, the New England Journal of Medicine (NEJM). This shows that the NEJM’s editorial board found his study as one of the most meaningful in improving medical practice and patient care to the world from among all papers it published in 2017.

 

Furthermore, Professor Mok published a study in 2014 proving that molecular targeted therapy is superior to standard first-line chemotherapy in ALK-positive lung cancer patients. In 2017, he made another study that confirmed a novel targeted therapy improved the progression-free survival when compared with the standard treatment for ALK-positive lung cancer patients, setting the new standard of care for the patients throughout the world.

 

By understanding the molecular profile of lung cancer, physicians can customise the treatment for patients according to the genetic information of their tumours. This brings personalised medicine development of lung cancer into a new stage and enhances patients’ quality of life.

 

About American Society of Clinical Oncology

The American Society of Clinical Oncology (ASCO) was founded in 1964. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.

 

ASCO held its 54th annual meeting in Chicago, USA, from 1st to 5th of June in 2018. At the annual meeting, over 30,000 oncology experts around the globe participated to discuss the most advanced treatment options.

 

A global study led by Professor Tony MOK, Li Shu Fan Medical Foundation Professor of Clinical Oncology and Chairman of the Department of Clinical Oncology of the Faculty of Medicine at CUHK, has revealed that a second generation targeted therapy improves the overall survival of advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. The new treatment should be considered as one of the standard treatment options for these lung cancer patients. Professor MOK presented the study findings at the 54th ASCO annual meeting held in early June this year.

A global study led by Professor Tony MOK, Li Shu Fan Medical Foundation Professor of Clinical Oncology and Chairman of the Department of Clinical Oncology of the Faculty of Medicine at CUHK, has revealed that a second generation targeted therapy improves the overall survival of advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. The new treatment should be considered as one of the standard treatment options for these lung cancer patients. Professor MOK presented the study findings at the 54th ASCO annual meeting held in early June this year.

 Professor Tony MOK has made major breakthroughs in lung cancer research which are impactful on lung cancer treatment globally.

Professor Tony MOK has made major breakthroughs in lung cancer research which are impactful on lung cancer treatment globally.

More Press Releases

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

Research
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Symposium
CUHK Study Finds Half of Childhood Cancer Survivors Used Complementary and Alternative Medicine

CUHK Study Finds Half of Childhood Cancer Survivors Used Complementary and Alternative Medicine

Research
Insights into B-cells and GPR18 Gene Expression by CU Medicine team  Improve Prediction of Survival in Multiple Cancer Types

Insights into B-cells and GPR18 Gene Expression by CU Medicine team Improve Prediction of Survival in Multiple Cancer Types

Research
CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

Research
Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Response
李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

Donation
CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

Health Campaign
CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

Research
Two CUHK Research Projects Receive State Science and Technology Awards

Two CUHK Research Projects Receive State Science and Technology Awards

Awards and honors
CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

Research
CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

Research
CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

Research
The 7th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Palliative Care in the Community’

The 7th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Palliative Care in the Community’

Symposium
CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

Research
CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

Research
CUHK and HKU Host the 5th Annual Palliative Care Symposium for Health Care Workers in Chinese Population

CUHK and HKU Host the 5th Annual Palliative Care Symposium for Health Care Workers in Chinese Population

Symposium
CUHK Pioneers Innovative Computer Assisted Tumor Surgery for Bone Cancer Patients

CUHK Pioneers Innovative Computer Assisted Tumor Surgery for Bone Cancer Patients

Surgical advancement
Bowel Cancer Will Become Top Cancer in Hong Kong CUHK Introduces Colon Pill Camera to Prevent Bowel Cancer

Bowel Cancer Will Become Top Cancer in Hong Kong CUHK Introduces Colon Pill Camera to Prevent Bowel Cancer

Surgical advancement
CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

Clinical service
The Chinese University of Hong Kong Nethersole School of Nursing hosts the Fifth Pan-Pacific Nursing Conference and Seventh Nursing Symposium on Cancer Care

The Chinese University of Hong Kong Nethersole School of Nursing hosts the Fifth Pan-Pacific Nursing Conference and Seventh Nursing Symposium on Cancer Care

Symposium
Predicting Your Colorectal-polyp Risk with CUHK Colorectal-polyp Prediction Index (CU-CPI)

Predicting Your Colorectal-polyp Risk with CUHK Colorectal-polyp Prediction Index (CU-CPI)

Clinical service

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.